Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)

References

• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138.
   PubMed Web of Science ®Google Scholar
• Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110.
   PubMedGoogle Scholar
• Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293.
   PubMed Web of Science ®Google Scholar
• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–498.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66.
   PubMed Web of Science ®Google Scholar
• Sibbald C, Drucker AM. Patient burden of atopic dermatitis. Dermatol Clin. 2017;35(3):303–316.
   PubMed Web of Science ®Google Scholar
• LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol. 2019;36(1):36–65.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878.
   PubMed Web of Science ®Google Scholar
• Bruin-Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32(2):164–173.
   PubMed Web of Science ®Google Scholar
• Bruin-Weller M, Pink AE, Patrizi A, et al. EUROSTAD prospective observational study: baseline characteristics, atopic dermatitis severity, and patient-reported outcomes. J Am Acad Dermatol. 2019;81(4):AB58.
   Web of Science ®Google Scholar
• Rehal B, Armstrong AW, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLOS One. 2011;6(4):e17520.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11–18.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769.
   PubMed Web of Science ®Google Scholar
• Basra MK, Fenech R, Gatt RM, et al. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.
   PubMed Web of Science ®Google Scholar
• Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
   PubMed Web of Science ®Google Scholar
• Rabin R, Gudex C, Selai C, et al. From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire. Value Health. 2014;17(1):70–76.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–1036.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Lötvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–1279.
   PubMed Web of Science ®Google Scholar
• Eckert L, Gupta S, Gadkari A, et al. Burden of illness in adults with atopic dermatitis: analysis of national health and wellness survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187–195.
   PubMed Web of Science ®Google Scholar
• Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290–300.
   PubMed Web of Science ®Google Scholar
• Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381–388.e2.
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40–45.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, Ariëns LFM, Schaft J, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry. Allergy. 2020;75(9):2376–2379.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Huang A, Wang L, et al. Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. PLOS One. 2019;14(1):e0210517.
   PubMed Web of Science ®Google Scholar
• Law Ping Man S, Bouzillé G, Beneton N, et al. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. J Eur Acad Dermatol Venereol. 2018;32(8):1327–1335.
   PubMed Web of Science ®Google Scholar